Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004134 (
ataxia
)
15,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The cerebellar variant of multiple system atrophy (MSA-C) has overlapping clinical features with the hereditary spinocerebellar ataxias (SCAs), but can usually be distinguished on a clinical basis. We describe a patient who developed a sporadic, late-onset, rapidly progressive neurodegenerative disorder consistent with MSA-C. Genetic testing, however, showed an abnormal expansion of one allele of the spinocerebellar
ataxia
3 (SCA3) gene. The clinical impression of MSA-C was confirmed by identification of numerous
alpha-synuclein
-containing glial cytoplasmic inclusions on autopsy. These findings suggest that abnormal expansion of the SCA3 gene may be a risk factor for the development of MSA-C.
...
PMID:Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. 1713 18
Multiple system atrophy (MSA) is a sporadic neurodegenerative disease manifested clinically by progressive
ataxia
, parkinsonism, and autonomic dysfunction. Its cause is unknown, and there is no curative therapy.
Alpha-synuclein
is an important protein forming aggregations called glial cytoplasmic inclusions (GCIs) in oligodendroglia; these aggregations are considered important in MSA pathogenesis. Overexpression of the human
alpha-synuclein
gene in mice induces the formation of GCI-like aggregations in oligodendrocytes, leading mice to exhibit neurological signs similar to those in MSA patients. However, previous studies have excluded mutations within the coding region of the
alpha-synuclein
gene in MSA patients. To determine whether alteration in the expression level of the
alpha-synuclein
gene is associated with MSA pathogenesis, we used TaqMan quantitative PCR assay to analyze the
alpha-synuclein
gene copy number in patients' genomes. We also used quantitative RT-PCR and in situ hybridization to analyze
alpha-synuclein
mRNA expression in MSA patients' brain tissues. We found no alteration in the
alpha-synuclein
gene copy number in the patients' genomes (n = 50). Quantitative analysis for
alpha-synuclein
mRNA by the TaqMan method showed that
alpha-synuclein
mRNA levels were comparable between control (n = 3) and MSA (n = 3) cerebella. On in situ hybridization, the number of neurons with
alpha-synuclein
mRNA expression was no greater in the cerebella of MSA patients (n = 3) than in the controls (n = 3). However, GCIs were seen in these MSA specimens on immunohistochemistry for
alpha-synuclein
. These results suggest that
alpha-synuclein
gene expression is not the fundamental cause of MSA.
...
PMID:Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. 1984 60
Multiple system atrophy (MSA) is a sporadic alpha-synucleinopathy clinically characterized by variable degrees of parkinsonism, cerebellar ataxia and autonomic dysfunction. The histopathological hallmark of MSA is glial cytoplasmic inclusion (GCI). It is considered to represent the earliest stage of the degenerative process in MSA and to precede neuronal degeneration. Sporadic Creutzfeldt-Jakob disease (sCJD) is a fatal, rapidly progressive dementia generally associated with
ataxia
, pyramidal and extrapyramidal symptoms and myoclonus. Definite diagnosis needs neuropathological demonstration of variable degrees of spongiform degeneration of neuropil, neuronal loss, astro- and microgliosis, and the presence of abnormal deposits of the misfolded prion protein PrP(res) . Both diseases, CJD and MSA are infrequent among neurodegenerative diseases. In the present report we describe clinical and neuropathological findings of a previously healthy 64-year-old woman who developed symptoms of classical CJD. At post mortem examination, the brain showed in addition to classical methionine/methionine PrP(res) type 1 (MM1) sCJD changes and moderate Alzheimer-type pathology, features of "preclinical" MSA with minimal histopathological changes. These were characterized by discrete amounts of
alpha-synuclein
immunoreacive glial cytoplasmic inclusions in the striato-nigral system, isolated intraneuronal inclusions in pigmented neurons of the substantia nigra, as well as some vermiform intranuclear inclusions. To our knowledge, this is the first report on the coexistence of definite sCJD and "minimal changes" MSA in the same patient.
...
PMID:"Preclinical" MSA in definite Creutzfeldt-Jakob disease. 2169 62
<< Previous
1
2